Antifungal Use in Oncohematological Neutropenic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
Invader Fungal Infection
Interventions
DRUG

Antifungal drug. VORICONAZOL. (VFEND®)

I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)

Trial Locations (13)

Unknown

Hospital Clínic, Barcelona

Hospital Universitario Marqués de Valdecilla, Santander

Hospital General de Jerez de la Frontera, Jerez de la Frontera

Hospital Virgen de las Nieves, Granada

Hospital General Universitario Gregorio Marañón, Madrid, Madrid

Hospital Universitario de la Princesa, Madrid

Hospital Universitario Ramón y Cajal, Madrid, Madrid

Hospital Son Llatzer, Palma de Mallorca

Hospital Universitario Morales Meseguer, Murcia, Murcia

Hospital Clínico Universitario de Valencia, Valencia

Hospital Universitario La Fe, Valencia

Hospital Clínico Lozano Blesa, Zaragoza

Hospital Clínico Universitario de Salamanca, Salamanca

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT00386802 - Antifungal Use in Oncohematological Neutropenic Patients | Biotech Hunter | Biotech Hunter